EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance

Fabian Fröhlich iD, Luca Gerosa iD, Jeremy Muhlich iD, Peter K Sorger iD

Molecular Systems Biology · 10.02.2023 · 19 (2)

DOI: 10.15252/msb.202210988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Systems Biology, online erschienen am 26.01.2023. Verfasst von Fabian Fröhlich und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS ¦ NIH ¦ National Cancer Institute, Human Frontier Science Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF is prototypical of oncogenes that can be targeted therapeutically and the treatment of BRAF V600E melanomas with RAF and MEK inhibitors results in rapid tumor regression. However, drug‐induced rewiring generates a drug adapted state thought to be involved in acquired resistance and disease recurrence. In this article, we study mechanisms of adaptive rewiring in BRAF V600E melanoma cells using an energy‐based implementation of ordinary differential equation (ODE) modeling in combination with proteomic, transcriptomic and imaging data. We develop a method for causal tracing of ODE models and identify two parallel MAPK reaction channels that are differentially sensitive to RAF and MEK inhibitors due to differences in protein oligomerization and drug binding. We describe how these channels, and timescale separation between immediate‐early signaling and transcriptional feedback, create a state in which the RAS‐regulated MAPK channel can be activated by growth factors under conditions in which the BRAF V600E ‐driven channel is fully inhibited. Further development of the approaches in this article is expected to yield a unified model of adaptive drug resistance in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafHumansCell Line, TumorDrug Resistance, NeoplasmMAP Kinase Signaling SystemMitogen-Activated Protein Kinase KinasesMutationNeoplasm Recurrence, LocalProtein Kinase InhibitorsProteomics

Stichwörter der Autor:innen

MAPK pathwayallosteric interactionsdrug resistancekinetic modelingrewiring

Substanzen

Mitogen-Activated Protein Kinase KinasesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Fabian Fröhlich, Luca Gerosa, Jeremy Muhlich, Peter K Sorger

Förderung

  • NCI NIH HHS
  • HHS ¦ NIH ¦ National Cancer Institute
  • Human Frontier Science Program
  • Novartis Foundation

Zitieren

APA

Fröhlich, F., Gerosa, L., Muhlich, J., & Sorger, P. K. (2023). Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance. Molecular Systems Biology, 19(2). https://doi.org/10.15252/msb.202210988

Vancouver

Fröhlich F, Gerosa L, Muhlich J, Sorger PK. Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance. Molecular Systems Biology. 2023;19(2). doi:10.15252/msb.202210988

BibTeX
@article{Frhlich2023,
  author = {Fröhlich, Fabian and Gerosa, Luca and Muhlich, Jeremy and Sorger, Peter K},
  title = {Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance},
  journal = {Molecular Systems Biology},
  year = {2023},
  volume = {19},
  number = {2},
  doi = {10.15252/msb.202210988}
}
Kostenlos starten →